171 related articles for article (PubMed ID: 27998978)
1. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
2. Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry.
Bhuria V; Franz T; Baldauf C; Böttcher M; Chatain N; Koschmieder S; Brümmendorf TH; Mougiakakos D; Schraven B; Kahlfuß S; Fischer T
Cell Commun Signal; 2024 Mar; 22(1):186. PubMed ID: 38509561
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.
Abraham BG; Haikarainen T; Vuorio J; Girych M; Virtanen AT; Kurttila A; Karathanasis C; Heilemann M; Sharma V; Vattulainen I; Silvennoinen O
Sci Adv; 2024 Mar; 10(10):eadl2097. PubMed ID: 38457493
[TBL] [Abstract][Full Text] [Related]
4. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Pomicter AD; Eiring AM; Senina AV; Zabriskie MS; Marvin JE; Prchal JT; O'Hare T; Deininger MW
Exp Hematol; 2015 Jul; 43(7):537-45.e1-11. PubMed ID: 25912019
[TBL] [Abstract][Full Text] [Related]
5. Signals mediating Klotho-induced neuroprotection in hippocampal neuronal cells.
Cheng MF; Chen LJ; Niu HS; Yang TT; Lin KC; Cheng JT
Acta Neurobiol Exp (Wars); 2015; 75(1):60-71. PubMed ID: 25856523
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.
Haage TR; Charakopoulos E; Bhuria V; Baldauf CK; Korthals M; Handschuh J; Müller P; Li J; Harit K; Nishanth G; Frey S; Böttcher M; Fischer KD; Dudeck J; Dudeck A; Lipka DB; Schraven B; Green AR; Müller AJ; Mougiakakos D; Fischer T
J Hematol Oncol; 2024 Jun; 17(1):43. PubMed ID: 38853260
[TBL] [Abstract][Full Text] [Related]
7. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
Oh ST; Simonds EF; Jones C; Hale MB; Goltsev Y; Gibbs KD; Merker JD; Zehnder JL; Nolan GP; Gotlib J
Blood; 2010 Aug; 116(6):988-92. PubMed ID: 20404132
[TBL] [Abstract][Full Text] [Related]
8. Epo-IGF1R cross talk expands stress-specific progenitors in regenerative erythropoiesis and myeloproliferative neoplasm.
Hsieh HH; Yao H; Ma Y; Zhang Y; Xiao X; Stephens H; Wajahat N; Chung SS; Xu L; Xu J; Rampal RK; Huang LJ
Blood; 2022 Dec; 140(22):2371-2384. PubMed ID: 36054916
[TBL] [Abstract][Full Text] [Related]
9. Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven activation from cytokine-induced stimulation.
Papadopoulos N; Pristavec A; Nédélec A; Levy G; Staerk J; Constantinescu SN
Blood; 2023 Nov; 142(21):1818-1830. PubMed ID: 37616564
[TBL] [Abstract][Full Text] [Related]
10. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.
Usart M; Stetka J; Luque Paz D; Hansen N; Kimmerlin Q; Almeida Fonseca T; Lock M; Kubovcakova L; Karjalainen R; Hao-Shen H; Börsch A; El Taher A; Schulz J; Leroux JC; Dirnhofer S; Skoda RC
Blood; 2024 Jun; 143(24):2490-2503. PubMed ID: 38493481
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
Varghese LN; Ungureanu D; Liau NP; Young SN; Laktyushin A; Hammaren H; Lucet IS; Nicola NA; Silvennoinen O; Babon JJ; Murphy JM
Biochem J; 2014 Mar; 458(2):395-405. PubMed ID: 24354892
[TBL] [Abstract][Full Text] [Related]
12. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
Kilpivaara O; Mukherjee S; Schram AM; Wadleigh M; Mullally A; Ebert BL; Bass A; Marubayashi S; Heguy A; Garcia-Manero G; Kantarjian H; Offit K; Stone RM; Gilliland DG; Klein RJ; Levine RL
Nat Genet; 2009 Apr; 41(4):455-9. PubMed ID: 19287384
[TBL] [Abstract][Full Text] [Related]
13. SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm.
Yang Y; Abbas S; Sayem MA; Dutta A; Mohi G
Blood Cancer J; 2023 Nov; 13(1):171. PubMed ID: 38012156
[TBL] [Abstract][Full Text] [Related]
14. Shengmaisan combined with Liuwei Dihuang Decoction alleviates chronic intermittent hypoxia-induced cognitive impairment by activating the EPO/EPOR/JAK2 signaling pathway.
Si J; Chen X; Qi K; Li D; Liu B; Zheng Y; Ji E; Yang S
Chin J Nat Med; 2024 May; 22(5):426-440. PubMed ID: 38796216
[TBL] [Abstract][Full Text] [Related]
15. [leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) inhibits proliferation and promotes apoptosis of human HEL cells with JAK2 V617F mutation by blocking the JAK/STAT and PI3K/AKT signaling pathways].
Fan C; Zhang Y; Yang R; Wu X; Zhou J; Xue J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Mar; 40(3):207-214. PubMed ID: 38512030
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Quintás-Cardama A; Verstovsek S
Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
[TBL] [Abstract][Full Text] [Related]
17. Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2
Yuan J; Song J; Chen C; Lv X; Bai J; Yang J; Zhou Y
Invest New Drugs; 2022 Dec; 40(6):1194-1205. PubMed ID: 36044173
[TBL] [Abstract][Full Text] [Related]
18. MAPK-negative feedback regulation confers dependence to JAK2
Kesarwani M; Kincaid Z; Azhar M; Menke J; Schwieterman J; Ansari S; Reaves A; Deininger ME; Levine R; Grimes HL; Azam M
Leukemia; 2023 Aug; 37(8):1686-1697. PubMed ID: 37430058
[TBL] [Abstract][Full Text] [Related]
19. Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
Wan X; Ma Y; McClendon CL; Huang LJ; Huang N
PLoS Comput Biol; 2013 Apr; 9(4):e1003022. PubMed ID: 23592968
[TBL] [Abstract][Full Text] [Related]
20. Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice.
Fisher DAC; Laranjeira ABA; Kong T; Snyder SC; Shim K; Fulbright MC; Oh ST
Exp Hematol; 2023 Dec; 128():48-66. PubMed ID: 37611729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
